<DOC>
	<DOC>NCT02244372</DOC>
	<brief_summary>The investigators performed randomized, double-blind, placebo-controlled human trial to evaluate the efficacy and safety of Cordyceps sinensis mycelium culture extract (Paecilomyces hepiali, CBG-CS-2) on promotion of immunity. The investigators measured promotion of immunity parameters , including Cytotoxicity, Cytokine (IL-4, IL-6, IL-12, IFN-γ, TNF-α), hs-CRP, antibody titer, and upper respiratory tract infection(URI)</brief_summary>
	<brief_title>Efficacy and Safety of Cordyceps Sinensis Mycelium Culture Extract(Paecilomyces Hepiali, CBG-CS-2) on Promotion of Immunity</brief_title>
	<detailed_description />
	<criteria>Males and females 2080 years old Who had suffered more than twice Upper respiratory infection* disorder or common cold causing URI Able to give informed consent WBC concentration below 3000 ㎕ Subjects vaccinated against influenza within the last 6 months prior to the study Subjects with Upper respiratory infection at screening visit Subjects with BMI ＜ 18.5 kg/m2 at screening visit Allergic or hypersensitive to any of the ingredients in the test products Diagnosed of gastrointestinal disease such as Immunerelated diseases, severe hepatic, renal failure, and diabetes History of reaction to any of the test products or of gastrointestinal diseases such as Crohn's disease or gastrointestinal surgery History of alcohol or substance abuse Participation in any other clinical trials within past 2 months Laboratory test, medical or psychological conditions deemed by the investigators to interfere with successful participation in the study Pregnant or lactating women etc.</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>Cordyceps sinensis mycelium culture extract(Paecilomyces hepiali, CBG-CS-2)</keyword>
	<keyword>immunity</keyword>
</DOC>